

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/869,820	07/05/2001	Nancy A. Noble	304344USWO	8977	
26941	7590 . 01/05/2004		EXAMINER		
MANDEL & ADRIANO			MCGARRY, SEAN		
55 SOUTH LAKE AVENUE SUITE 710			ART UNIT	PAPER NUMBER	
	A, CA 91101		1635		
·			DATE MAILED: 01/05/200	DATE MAILED: 01/05/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

•					
	Application No.	Applicant(s)			
	09/869,820	NOBLE ET AL.			
Office Action Summary	Examiner	Art Unit			
	Sean R McGarry	1635			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, - Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).  Status	36(a). In no event, however, may a reply be to within the statutory minimum of thirty (30) day will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDON	imely filed  ays will be considered timely.  m the mailing date of this communication.  IED (35 U.S.C. § 133).			
1) Responsive to communication(s) filed on <u>08 Sectors</u>	eptember 2003.				
2a)☐ This action is <b>FINAL</b> . 2b)☐ This	action is non-final.				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims					
4)  Claim(s) <u>1,2,4-24 and 26-55</u> is/are pending in t 4a) Of the above claim(s) <u>5,7,8,14,24,27-29 and</u> 5)  Claim(s) is/are allowed. 6)  Claim(s) is/are rejected. 7)  Claim(s) is/are objected to. 8)  Claim(s) <u>1, 2, 46, 9-13, 15-20, 22, 23, 26, 30-3</u>	<u>d 35-54</u> is/are withdrawn from c				
Application Papers					
9)☐ The specification is objected to by the Examiner.					
10)☐ The drawing(s) filed on is/are: a)☐ acc	epted or b) objected to by the	Examiner.			
Applicant may not request that any objection to the					
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).					
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.					
Priority under 35 U.S.C. §§ 119 and 120  12)					
a) All b) Some * c) None of:  1. Certified copies of the priority documents  2. Certified copies of the priority documents  3. Copies of the certified copies of the priority application from the International Bureau  * See the attached detailed Office action for a list  13) Acknowledgment is made of a claim for domesti since a specific reference was included in the first 37 CFR 1.78.  a) The translation of the foreign language pro  14) Acknowledgment is made of a claim for domesti reference was included in the first sentence of the	s have been received. s have been received in Applica rity documents have been receiv u (PCT Rule 17.2(a)). of the certified copies not receiv c priority under 35 U.S.C. § 119 st sentence of the specification of evisional application has been re- c priority under 35 U.S.C. §§ 12	ved in this National Stage  ved.  (e) (to a provisional application)  or in an Application Data Sheet.  eceived.  0 and/or 121 since a specific			
Attachment(s)	<b></b> -				
Notice of References Cited (PTO-892)     Notice of Draftsperson's Patent Drawing Review (PTO-948)     Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal	ry (PTO-413) Paper No(s) Patent Application (PTO-152)			

Application/Control Number: 09/869,820

Art Unit: 1635

## Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1, 2, 4, 6, 9-13, 15-20, 22, 23, 26, and 55, drawn to a method of treating a condition associated with the excess accumulation of extracellular matrix via the administration of a first agent that inhibits TGFbeta associated accumulation extracellular matrix and a second agent that degrades extracellular matrix.

Group II, claim(s) 32-34, drawn to a method of treating or preventing a condition associated with excess TGF beta associated accumulation of extracellular matrix via the administration of a combination of at least two agents that inhibit accumulation of TGFbeta associated extracellular matrix which combination inhibits TGF beta associated extracellular accumulation in greater amounts that either agent alone.

The inventions listed as Groups I and II do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The reasons are the same as set forth in the restriction mailed 2/6/03. These two groups correspond to the groups I and II of the original restriction requirement. It is noted that these original groups were combined in the Official Action mailed 6/4/03, however applicant's amendments to the claims in the response filed 9/08/03 have rendered the new groups so distinct as to now require a new and different search for each invention. Further it is noted that the inventions are now unrelated since Group I is directed to the use of two different agents where the first agent inhibits extracellular matrix accumulation and the second degrades extracellular matrix proteins, for example. In group II the invention uses two different agents that have the capacity for increased inhibition of inhibiting extracellular matrix in combination. It is clear that these two different inventions as they stand after the amendments filed 9/08/03, now clearly lack a special technical feature, for the reasons of record and since they do not use the same combinations of compounds in the respective methods.

Art Unit: 1635

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sean R McGarry whose telephone number is (703)305-7028. The examiner can normally be reached on M-Th (6:00-4:30).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, John LeGuyader can be reached on (703) 308-0447. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

SRM